Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals
Therefore, this drug class controls dysglycaemia in people with T2D
The hypoglycaemic effect of GLP-1RAs is achieved by stimulating insulin secretion in pancreatic cells, suppressing glucagon secretion in pancreatic cells, and slowing gastric emptying
This discouraged the pharmaceutical industry from developing such drugs and undermined the FDA's willingness to approve them
Reliance Foundation Hospital, Mumbai, explains the euphoria: Newer agents in this family, and dual incretin drugs such as tirzepatide, have changed the conversation because, for the first time, we have medicines that can produce meaningful and, sometimes, dramatic weight reduction